In stealth Pharmaceutical Promotional Governance

Every claim pharma
makes is supposed to
trace to an authorized source.

Most of the time, it can't — not in ten minutes, not with an audit trail, and rarely across the jurisdictions where the claim actually lives. Two decades inside regulated industries, watching the gap between what companies say and what they can prove they said. That gap is what we are building to close.

Request a briefing →
The thesis

The cost of being wrong inside pharmaceutical promotion is rising — fast.

In 2025, the FDA issued over 200 enforcement letters challenging pharmaceutical advertising and promotion — the highest annual total in nearly 25 years. Seventy-four were directed specifically at pharma and biologic manufacturers. The enforcement environment is intensifying. The advisory clarity is declining.

The same pressure exists under every major promotional framework — the ABPI Code in the United Kingdom, the EU Pharma Package reforms, PAAB in Canada, Medicines Australia, PMDA in Japan. The multi-jurisdiction version is harder still. And the people inside global pharma who own this work have been carrying it with spreadsheets, local processes, and hope.

Built so hope is no longer the control.

Background

Every market carries its own interpretation of what a claim requires.

We have worked inside that variation — not around it. Across markets, frameworks, and the review cultures that make global promotional governance harder in practice than it looks in policy. That is the difference between knowing where the problem lives and mapping it from the outside.

Periya is built from that difference.

Contact

If you own compliance, promotional review, or the corpus behind it, we want to talk.

We are in stealth and not ready to show what we are building. What we are doing is having quiet, specific conversations with compliance, risk, audit, ethics, MLR, and promotional review leaders — across the US, EU, UK, and beyond — who have lived this problem firsthand. If that describes you, or the work you own, reach out directly.

hello@periya.ai →
For Pharmaceutical compliance, promotional review, MLR, risk, audit, and ethics leaders across global markets, and investors operating in this space.
Response Replies are personal and come directly from the founding team. No sales sequences.
Confidentiality Conversations are held in confidence. We do not publish, attribute, or share what we learn.